Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, gives his expert perspective on treatment advances in urothelial cancers.
Srikala S. Sridhar, MD, of the Princess Margaret Cancer Centre, summarizes important papers presented on bladder and urothelial cancers, including perspectives on immunotherapies and radiotherapies.
Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, summarizes a panel discussion on this important topic.
David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).
Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses in French a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499).
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.
